Semaglutide vs Tirzepatide
A side-by-side comparison drawn from public information and community discussion.
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two most-discussed GLP-1-class medications. The headline difference is mechanism: semaglutide targets one receptor, while tirzepatide targets two.
At a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| FDA-approved use | Type 2 diabetes; weight management (Wegovy) | Type 2 diabetes; weight management (Zepbound) |
| Dosing frequency | Once weekly injection | Once weekly injection |
| Results discussion | Strong appetite and weight effects commonly reported | Often discussed for larger average weight loss in head-to-head studies |
| Side effects | Mostly GI (nausea, constipation, diarrhea) | Mostly GI (nausea, diarrhea, constipation) |
| Typical cost | ~$900–$1,400/mo list by brand | ~$1,000–$1,300/mo list by brand |
Common questions
Is tirzepatide more effective than semaglutide?
Some studies suggest tirzepatide produces larger average weight loss, but individual results vary and neither is universally better. Tolerance, cost, coverage, and your prescriber's judgment all matter. Discuss your situation with a healthcare professional.
Do they have different side effects?
Both are associated mainly with gastrointestinal effects such as nausea, diarrhea, and constipation, usually most noticeable during titration. How any individual responds varies.
Discuss it with the community
Compare experiences and ask questions: